| Old Articles: <Older 8161-8170 Newer> |
|---|
 |
The Motley Fool
December 22, 2011
Brian Orelli |
VIVUS' Obese Pink Elephant Qnexa data can't be ignored.   |
The Motley Fool
December 22, 2011
Rebecca Lipman |
Teva Announces $3 Billion Share Buyback: 4 Buyback Stocks for Your Watchlist These buyback stocks have a track record of being more profitable than their competitors -- does that make their outlook even more bullish? |
The Motley Fool
December 21, 2011
Brian Orelli |
A Biotech Garage Sale Exelixis sells off a preclinical program. |
The Motley Fool
December 21, 2011
Brian Orelli |
Knocked Down? Not for Long! Last week shares of Antares Pharma got knocked down after BioSante Pharmaceuticals' LibiGel didn't live up to expectations. |
The Motley Fool
December 20, 2011
Brian Orelli |
If You Can't Beat 'Em, Join 'Em: Amgen Goes Generic Biosimilars are coming -- might as well get a piece of the action. |
The Motley Fool
December 20, 2011
Brian Orelli |
What's Up With the Back-Slapping, Sequenom? Some sales numbers would be nice. |
The Motley Fool
December 20, 2011
Luke Timmerman |
Amgen, Watson Strike $400M Deal for Biosimilar Cancer Drugs What does this important collaboration mean for biosimilars? |
The Motley Fool
December 20, 2011
Brian D. Pacampara |
Salix Pharmaceuticals Shares Popped: What You Need to Know Shares of drugmaker Salix Pharmaceuticals climbed as high as 10.5% on Tuesday after the company reported positive phase-3 data for an oral version of its constipation treatment, Relistor. |
The Motley Fool
December 19, 2011
Brian Orelli |
Elan Turns It Around in 2011 Let's hope next year is as productive. |
The Motley Fool
December 19, 2011
Brian Orelli |
ARIAD's Prolific 2011 The biotech is doing something right. |
| <Older 8161-8170 Newer> Return to current articles. |
